Fierce Biotech article highlights dearth of inclusion in Alzheimer’s research
“Alzheimer’s meds are here. But for the Down syndrome community, it’s still the 1980s” by Annalee Armstrong, Fierce Biotech An
March 2, 2023
“Alzheimer’s meds are here. But for the Down syndrome community, it’s still the 1980s” by Annalee Armstrong, Fierce Biotech An
2/22/2023 (Burlington, MA) – Today the LuMind IDSC Foundation, a leading national Down syndrome research organization, announced a new collaboration
The LuMind IDSC community and caregivers across the U.S. participated in “Challenges of Caregiving,” an online survey of caregiver perspectives
Dear Friend of LuMind IDSC, Recently, I spoke with a family whose newborn baby had heart surgery. As many of
On Friday, January 6, the U.S. Food & Drug Administration (FDA) granted accelerated approval for lecanemab, an anti-amyloid drug to
Our Impact Report 2022 highlights our accomplishments as an organization during a remarkable year. 2022 saw Down syndrome research receive
At an Alzheimer’s disease research conference last week, new clinical trial data was presented for an antibody drug candidate called
LuMind IDSC and the Down Syndrome Clinical Trials Network are pleased to announce the launch of the DS-CTN Data and
Eisai, a Japanese pharmaceutical company, and its partner Biogen, a Massachusetts-based biotechnology company, recently announced positive “topline” results from the
Long-COVID in adults with intellectual disability In a recent report, the National Task Group on Intellectual Disabilities and Dementia Practices